Drugs / PF-07265803
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05286281 | Mar → May 2022 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07265803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05286281 ↗ |
| Known as | ARRY-371797 | “The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy...” NCT05286281 ↗ |
| Action | Inhibit | “PF-07265803 is a p38 inhibitor formulated for oral delivery.” NCT05286281 ↗ |
| Route | Oral | “PF-07265803 is a p38 inhibitor formulated for oral delivery.” NCT05286281 ↗ |